Goldman Sachs
BBIO icon

Goldman Sachs’s BridgeBio Pharma BBIO Stock Holding History

Goldman Sachs’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135M Sell
1,814,657
-83,059
-4% -$5.82M 0.01% 997
2026
Q1 		$141M Buy
1,897,716
+114,883
+6% +$8.33M 0.02% 850
2025
Q4 		$136M Sell
1,782,833
-426,326
-19% -$28M 0.02% 814
2025
Q3 		$115M Sell
2,209,159
-412,092
-16% -$20.1M 0.01% 853
2025
Q2 		$113M Buy
2,621,251
+397,943
+18% +$14.5M 0.02% 821
2025
Q1 		$76.9M Buy
2,223,308
+188,119
+9% +$6.34M 0.01% 931
2024
Q4 		$55.8M Sell
2,035,189
-16,784
-0.8% -$434K 0.01% 1199
2024
Q3 		$52.2M Sell
2,051,973
-246,066
-11% -$6.46M 0.01% 1211
2024
Q2 		$58.2M Buy
2,298,039
+672,280
+41% +$18.4M 0.01% 1062
2024
Q1 		$50.3M Sell
1,625,759
-1,640,876
-50% -$55.8M 0.01% 1167
2023
Q4 		$132M Buy
3,266,635
+1,841,478
+129% +$55.3M 0.02% 639
2023
Q3 		$37.6M Buy
1,425,157
+399,689
+39% +$11.3M 0.01% 1301
2023
Q2 		$17.6M Buy
1,025,468
+50,237
+5% +$756K ﹤0.01% 1959
2023
Q1 		$16.2M Sell
975,231
-380,065
-28% -$4.43M ﹤0.01% 2001
2022
Q4 		$10.3M Buy
1,355,296
+145,086
+12% +$1.39M ﹤0.01% 2559
2022
Q3 		$12M Buy
1,210,210
+254,698
+27% +$2.65M ﹤0.01% 2333
2022
Q2 		$8.68M Buy
955,512
+232,765
+32% +$1.95M ﹤0.01% 2650
2022
Q1 		$7.34M Buy
722,747
+9,839
+1% +$101K ﹤0.01% 2993
2021
Q4 		$11.9M Buy
712,908
+94,369
+15% +$3.99M ﹤0.01% 2600
2021
Q3 		$29M Buy
618,539
+186,906
+43% +$10M 0.01% 1717
2021
Q2 		$26.3M Sell
431,633
-174,935
-29% -$9.99M 0.01% 1807
2021
Q1 		$37.4M Sell
606,568
-19,917
-3% -$1.3M 0.01% 1403
2020
Q4 		$44.5M Buy
626,485
+57,158
+10% +$2.76M 0.01% 1204
2020
Q3 		$21.4M Buy
569,327
+195,858
+52% +$6.16M 0.01% 1693
2020
Q2 		$12.2M Sell
373,469
-54,090
-13% -$1.65M ﹤0.01% 2115
2020
Q1 		$12.4M Buy
427,559
+201,500
+89% +$6.25M ﹤0.01% 1903
2019
Q4 		$7.92M Buy
226,059
+55,177
+32% +$1.53M ﹤0.01% 2609
2019
Q3 		$3.67M Buy
170,882
+32,544
+24% +$900K ﹤0.01% 3088
2019
Q2 		$3.73M Buy
+138,338
New +$3.77M ﹤0.01% 3065

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Goldman Sachs's BBIO Position: Q2 2026 in Review

Goldman Sachs reduced its BridgeBio Pharma (BBIO) stake by 4.4% in Q2 2026, selling an estimated $5.82M and leaving 1,814,657 shares worth $135M. The position accounts for 0.01% of the portfolio, ranked #997.

Goldman Sachs first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $141M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Goldman Sachs held 1,814,657 shares of BridgeBio Pharma worth $135M as of Q2 2026.
  • Goldman Sachs sold 83,059 BridgeBio Pharma shares in Q2 2026, an estimated $5.82M.
  • BridgeBio Pharma made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #997 holding.
  • Goldman Sachs first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • Goldman Sachs's BridgeBio Pharma position peaked at $141M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.